Literature DB >> 31386003

Impact of mass effect, tumor location, age, and surgery on the cognitive outcome of patients with high-grade gliomas: a longitudinal study.

Monica Dallabona1, Silvio Sarubbo1, Stefano Merler1, Francesco Corsini1, Giuseppe Pulcrano1, Umberto Rozzanigo1, Mattia Barbareschi1, Franco Chioffi1.   

Abstract

BACKGROUND: High-grade gliomas are the most frequently occurring brain tumors and carry unfavorable prognosis. Literature is controversial regarding the effects of surgery on cognitive functions.
METHODS: We analyzed a homogenous population of 30 patients with high-grade glioma who underwent complete resection. Patients underwent extensive neuropsychological analysis before surgery, 7 days after surgery, and approximately 40 days after surgery, before adjuvant treatments. Thirty-four neuropsychological tests were administered in the language, memory, attention, executive functions, and praxis domains.
RESULTS: The preoperative percentage of patients with impairment in the considered tests ranged from 0% to 53.3% (mean 20.9%). Despite a general worsening at early follow-up, a significant recovery was observed at late follow-up. Preoperative performances in language and verbal memory tasks depended on the joint effect of tumor volume, volume of surrounding edema, and tumor localization, with major deficits in patients with left lateralized tumor, especially insular and temporal. Preoperative performances in attention and constructive abilities tasks depended on the joint effect of tumor volume, volume of surrounding edema, and patient age, with major deficits in patients ≥ 65 years old. Recovery at late follow-up depended on the volume of resected tumor, edema resorption, and patient age.
CONCLUSIONS: Longitudinal neuropsychological performance of patients affected by high-grade glioma depends, among other factors, on the complex interplay of tumor volume, volume of surrounding edema, tumor localization, and patient age. Reported results support the definition of criteria for surgical indication based on the above factors. They may be used to propose more customized surgical, oncological, and rehabilitative strategies.

Entities:  

Keywords:  cognitive functions; high-grade gliomas; neuropsychology; outcome; surgery

Year:  2017        PMID: 31386003      PMCID: PMC6655475          DOI: 10.1093/nop/npw030

Source DB:  PubMed          Journal:  Neurooncol Pract        ISSN: 2054-2577


  39 in total

Review 1.  Brain tumors.

Authors:  L M DeAngelis
Journal:  N Engl J Med       Date:  2001-01-11       Impact factor: 91.245

2.  Rey-Osterrieth complex figure: normative values in an Italian population sample.

Authors:  P Caffarra; G Vezzadini; F Dieci; F Zonato; A Venneri
Journal:  Neurol Sci       Date:  2002-03       Impact factor: 3.307

3.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

4.  Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression.

Authors:  Christina A Meyers; Kenneth R Hess
Journal:  Neuro Oncol       Date:  2003-04       Impact factor: 12.300

Review 5.  Current concepts in mild cognitive impairment.

Authors:  R C Petersen; R Doody; A Kurz; R C Mohs; J C Morris; P V Rabins; K Ritchie; M Rossor; L Thal; B Winblad
Journal:  Arch Neurol       Date:  2001-12

6.  Prospective study of neuropsychologic testing and quality-of-life assessment of adults with primary malignant brain tumors.

Authors:  C A Hahn; R H Dunn; P E Logue; J H King; C L Edwards; E C Halperin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-03-15       Impact factor: 7.038

7.  Neurobehavioral status and health-related quality of life in newly diagnosed high-grade glioma patients.

Authors:  M Klein; M J Taphoorn; J J Heimans; H M van der Ploeg; W P Vandertop; E F Smit; S Leenstra; C A Tulleken; W Boogerd; J S Belderbos; W Cleijne; N K Aaronson
Journal:  J Clin Oncol       Date:  2001-10-15       Impact factor: 44.544

8.  Prediction of neurocognitive outcome in adult brain tumor patients.

Authors:  Thomas A Kaleita; David K Wellisch; Timothy F Cloughesy; Judith M Ford; Donald Freeman; Thomas R Belin; Jeffrey Goldman
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

9.  Does brain tumor histology influence cognitive function?

Authors:  Anne E Kayl; Christina A Meyers
Journal:  Neuro Oncol       Date:  2003-10       Impact factor: 12.300

Review 10.  Cognitive deficits in adult patients with brain tumours.

Authors:  Martin J B Taphoorn; Martin Klein
Journal:  Lancet Neurol       Date:  2004-03       Impact factor: 44.182

View more
  11 in total

1.  Do neurocognitive impairments explain the differences between brain tumor patients and their proxies when assessing the patient's IADL?

Authors:  Quirien Oort; Linda Dirven; Sietske A M Sikkes; Neil Aaronson; Florien Boele; Christine Brannan; Jonas Egeter; Robin Grant; Martin Klein; Irene M Lips; Yoshitaka Narita; Hitomi Sato; Monika Sztankay; Günther Stockhammer; Andrea Talacchi; Bernard M J Uitdehaag; Jaap C Reijneveld; Martin J B Taphoorn
Journal:  Neurooncol Pract       Date:  2022-02-26

2.  Perioperative levetiracetam for seizure prophylaxis in seizure-naive brain tumor patients with focus on neurocognitive functioning.

Authors:  Elias Konrath; Franz Marhold; Wolfgang Kindler; Florian Scheichel; Branko Popadic; Katrin Blauensteiner; Bernadette Calabek; Elisabeth Freydl; Michael Weber; Robin Ristl; Katharina Hainz; Camillo Sherif; Stefan Oberndorfer
Journal:  BMC Neurol       Date:  2022-07-08       Impact factor: 2.903

Review 3.  A systematic review of cognitive function in patients with glioblastoma undergoing surgery.

Authors:  Rohitashwa Sinha; Jade Marie Stephenson; Stephen John Price
Journal:  Neurooncol Pract       Date:  2019-04-23

4.  Research on cognitive and sociocognitive functions in patients with brain tumours: a bibliometric analysis and visualization of the scientific landscape.

Authors:  Uwe Schlegel; Patrizia Thoma; Milena Pertz; Stoyan Popkirov
Journal:  Neurol Sci       Date:  2020-02-12       Impact factor: 3.307

5.  Presurgical Identification of Patients With Glioblastoma at Risk for Cognitive Impairment at 3-Month Follow-up.

Authors:  Sophie J M Rijnen; Elke Butterbrod; Geert-Jan M Rutten; Margriet M Sitskoorn; Karin Gehring
Journal:  Neurosurgery       Date:  2020-11-16       Impact factor: 4.654

6.  Patient-reported cognitive function before and after glioma surgery.

Authors:  Stine Schei; Ole Solheim; Øyvind Salvesen; Tor Ivar Hansen; Lisa Millgård Sagberg
Journal:  Acta Neurochir (Wien)       Date:  2022-06-06       Impact factor: 2.816

7.  Personal space regulation is affected by unilateral temporal lesions beyond the amygdala.

Authors:  Audrey Dureux; Luca Zigiotto; Silvio Sarubbo; Clément Desoche; Alessandro Farnè; Nadia Bolognini; Fadila Hadj-Bouziane
Journal:  Cereb Cortex Commun       Date:  2022-07-22

8.  Lesion-Function Analysis from Multimodal Imaging and Normative Brain Atlases for Prediction of Cognitive Deficits in Glioma Patients.

Authors:  Martin Kocher; Christiane Jockwitz; Philipp Lohmann; Gabriele Stoffels; Christian Filss; Felix M Mottaghy; Maximilian I Ruge; Carolin Weiss Lucas; Roland Goldbrunner; Nadim J Shah; Gereon R Fink; Norbert Galldiks; Karl-Josef Langen; Svenja Caspers
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

9.  Linking late cognitive outcome with glioma surgery location using resection cavity maps.

Authors:  Eef J Hendriks; Esther J J Habets; Martin J B Taphoorn; Linda Douw; Aeilko H Zwinderman; W Peter Vandertop; Frederik Barkhof; Martin Klein; Philip C De Witt Hamer
Journal:  Hum Brain Mapp       Date:  2018-01-29       Impact factor: 5.038

10.  Functional connectivity within glioblastoma impacts overall survival.

Authors:  Andy G S Daniel; Ki Yun Park; Jarod L Roland; Donna Dierker; James Gross; Joseph B Humphries; Carl D Hacker; Abraham Z Snyder; Joshua S Shimony; Eric C Leuthardt
Journal:  Neuro Oncol       Date:  2021-03-25       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.